臨床研究支援事業

CSP-A-TOP《骨粗鬆症至適療法研究支援事業》

Comprehensive Support Project for Adequate Treatment of Osteoporosis

成果一覧

J-05

JOINT-05

J Bone Miner Metab ; 2020, 38, 412–417.

Design of a randomized trial of teriparatide followed by alendronate:Japanese Osteoporosis Intervention Trial‑05 (JOINT‑05). Tanaka S, Mori S, Hagino H, Sugimoto T


J-04

JOINT-04

J Bone Miner Metab; 2021, 39:668-677. doi: 10.1007/s00774-021-01208-3.

Risk factors for incident vertebral fractures in osteoporosis pharmacotherapy: a 2-year, prospective, observational study.Hiroshi Hagino , Yukari Uemura , Satoshi Mori , Teruki Sone , Hiroaki Ohta , Toshitaka Nakamura

Curr Med Res Opin; 2020,36(11),1847-1859. doi: 10.1080/03007995.2020.1816537. Epub 2020 Sep 14

Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04. Yukari Uemura , Teruki Sone , Shiro Tanaka , Teruhiko Miyazaki , Mayumi Tsukiyama , Akira Taguchi , Satoshi Soen , Satoshi Mori , Hiroshi Hagino , Toshitsugu Sugimoto , Masao Fukunaga , Hiroaki Ohta , Toshitaka Nakamura , Hajime Orimo , Masataka Shiraki , Adequate Treatment of Osteoporosis (A-TOP) Research Group

J Bone Miner Metab ; 2019,37, 886–892.

Incidence of osteonecrosis of the jaw in Japanese osteoporosis patients taking minodronic acid. Taguchi A, Uemura Y, Imai T, Tanaka S, Ohta H, Nakamura T, Orimo H, Sugimoto T, Soen S, Shiraki M ,Adequate Treatment of Osteoporosis(A-TOP) research group.

J Bone Miner Metab; 2019,37(3),491-495. doi: 10.1007/s00774-018-0942-z. Epub 2018 Jul 17.

Study design of multi-center, open-label randomized controlled, head-to-headtrial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04. Uemura Y, Tanaka S, Miyazaki T, Tsukiyama M, Sone T, Taguchi A, Soen S, Moei S, Hagino H, Sugimoto T, Fukunaga M, Ohta H, Nakamura T, Orimo H, Shiraki M, Adequate Treatment of Osteoporosis (A-TOP) research group.


J-03

JOINT-03

Osteoporos Int; 2017,28(6),1893-1901.DOI 10,1007/S 00198-017-3966-7

Health state utility values and patient-reported outcomes before and after vertebral and non-vertebral fractures in an osteoporosis clinical trial. Imai T, Tanaka S, Kawakami K, Miyazaki T, Hagino H, Shiraki M, for the A-TOP(Adequate Treatment of Osteoporosis) Research Group.

J Bone Miner Metab ; 2017,35(4);385-395.DOI 10.1007/s00774-016-0768-5

Comparison of concurrent treatment with vitamin K2 and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03. Tanaka S, Miyazaki T, Uemura Y, Miyakawa N, Gorai I, Nakamura T, Fukunaga M, Ohashi Y, Ohta H, Mori S, Hagino H, Hosoi T, Sugimoto T, Itoi E, Orimo H, Shiraki M.

J Bone Miner Metab; 2014,32(3), 298-304.

Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03). Tanaka S, Miyazaki T, Uemura Y, Kuroda T, Miyakawa N, Nakamura T, Fukunaga M, Ohashi Y, Ohta H, Mori S, Hagino H, Hosoi T, Sugimoto T, Itoi E, Orimo H, Shiraki


J-02

JOINT-02

J Orthop Sci. ; 2020,S0949-2658(20)30332-8.

Impact of bone mineral density in reducing fracture risk in patients receiving alendronate plus alfacalcidol therapy. Eiji Itoi , Yukari Uemura , Hiroaki Ohta , Toshitaka Nakamura , Masao Fukunaga , Hajime Orimo , Masataka Shiraki .

Clin Therap; 2014,36(2),225-235.

Serum 25 hydroxyvitamin D level as an independent determinant of quality of life in osteoporosis with high risk for fracture. Ohta H, Uemura Y, Nakamura T, Fukunaga M, Ohashi Z, Hosoi T, Mori S, Sugimoto T, Itoi E, Orimo H, Shiraki M for the Adequate Treatment of Osteoporosis.(A-TOP)research group.

J Bone Miner Metab; 2015,33(6):,642-650.

Comparison of expert and nonexpert physicians in the assessment of vertebral fractures using the semiquantitative method in Japan. Uemura Y, Miyakawa N, Orimo H, Shiraki M, Nakamura T, Mori S.

Curr Med Res Opin; 2011,27(6),1273-84.

Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT)- 02. Orimo H, Nakamura T, Fukunaga M, Ohta H, Hosoi T, Uemura Y, Kuroda T, Miyakawa N, Ohashi Y, Shiraki M; A-TOP (Adequate Treatment of Osteoporosis)research group

J Bone Miner Metab; 2011,29(1),37-43.

Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures: rationale, aims and organization of a Japanese Osteoporosis Intervention Trial(JOINT) initiated by the Research Group of Adequate Treatment of Osteoporosis (A-TOP). Shiraki M, Kuroda T, Hosoi T, Ohashi Y, Ohta H, Fukunaga M, Nakamura T, Orimo H et al.


A-01

JOB

Jpn J Pharmacoepidemiol;21(1);13-19,2016,DOI.org/10.3820/jjpe.21.13

Validation Study of Claims-based Definitions of Suspected Atypical Femoral Fractures Using Clinical Information. Tanaka S, Hagino H, Ishizuka A, Miyazaki T, Yamamoto T, Hosoi T.